Saikosaponin‑d inhibits proliferation of DU145 human prostate cancer cells by inducing apoptosis and arresting the cell cycle at G0/G1 phase

Yao,Min; Yang,Jingbo; Cao,Lanqing; Zhang,Lian; Qu,Shanshan; Gao,Hongwen

doi:10.3892/mmr.2014.2153

Saikosaponin‑d inhibits proliferation of DU145 human prostate cancer cells by inducing apoptosis and arresting the cell cycle at G0/G1 phase

Authors:
- Min Yao
- Jingbo Yang
- Lanqing Cao
- Lian Zhang
- Shanshan Qu
- Hongwen Gao
View Affiliations

Affiliations: Department of Pathology, Jilin University Bethune Second Hospital, Changchun, Jilin 130041, P.R. China
Published online on: April 15, 2014 https://doi.org/10.3892/mmr.2014.2153
Pages: 365-372

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Saikosaponin‑d (SSd), a triterpene saponin compound derived from Bupleurum radix, has been shown to have a cytotoxic effect on various cancer cell lines. However, its effect on prostate cancer cells has remained unexplored. The present study reports the apoptosis‑inducing effect of SSd on the DU145 human prostate carcinoma cell line. Treatment with SSd inhibited DU145 cell proliferation in a concentration‑dependent manner. Flow cytometric analysis showed that SSd inhibited the proliferation of DU145 cells by induction of apoptosis and cell cycle arrest at G0/G1 phase. Further mechanistic experiments demonstrated that SSd arrested the cell cycle at G0/G1 phase via upregulation of p53 and p21 and induced apoptosis by modulating B‑cell lymphoma 2 family proteins, dissipation of the mitochondrial membrane potential, release of cytochrome c into the cytosol and activation of caspase‑3. In conclusion the present study indicated that SSd induced apoptosis in DU145 cells by the intrinsic apoptotic pathway. Therefore, SSd may become a leading candidate drug for the therapy of prostate carcinoma.

View Figures

View References

1	Lee J, Yang DH, Suh JH, Kim U, Eom HY, Kim J, Lee MY, Kim J and Han SB: Species discrimination of Radix Bupleuri through the simultaneous determination of ten saikosaponins by high performance liquid chromatography with evaporative light scattering detection and electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 879:3887–3895. 2011. View Article : Google Scholar
2	Kato M, Pu MY, Isobe K, Iwamoto T, Nagase F, Lwin T, Zhang YH, Hattori T, Yanagita N and Nakashima I: Characterization of the immunoregulatory action of saikosaponin-d. Cell Immunol. 159:15–25. 1994. View Article : Google Scholar
3	Kato M, Pu MY, Isobe K, Hattori T, Yanagita N and Nakashima I: Cell type-oriented differential modulatory actions of saikosaponin-d on growth responses and DNA fragmentation of lymphocytes triggered by receptor-mediated and receptor-bypassed pathways. Immunopharmacology. 29:207–213. 1995. View Article : Google Scholar
4	Chang JS, Wang KC, Liu HW, Chen MC, Chiang LC and Lin CC: Sho-saiko-to (Xiao-Chai-Hu-Tang) and crude saikosaponins inhibit hepatitis B virus in a stable HBV-producing cell line. Am J Chin Med. 35:341–351. 2007. View Article : Google Scholar : PubMed/NCBI
5	Ohtake N, Nakai Y, Yamamoto M, Sakakibara I, Takeda S, Amagaya S and Aburada M: Separation and isolation methods for analysis of the active principles of Sho-saiko-to (SST) oriental medicine. J Chromatogr B Analyt Technol Biomed Life Sci. 812:135–148. 2004. View Article : Google Scholar : PubMed/NCBI
6	Bao Y, Li C, Shen H and Nan F: Determination of saikosaponin derivatives in Radix bupleuri and in pharmaceuticals of the chinese multiherb remedy xiaochaihu-tang using liquid chromatographic tandem mass spectrometry. Anal Chem. 76:4208–4216. 2004. View Article : Google Scholar
7	Wu GC, Wu H, Fan LY and Pan HF: Saikosaponins: a potential treatment option for systemic lupus erythematosus. Ir J Med Sci. 180:259–261. 2011. View Article : Google Scholar : PubMed/NCBI
8	Hsu YL, Kuo PL, Chiang LC and Lin CC: Involvement of p53, nuclear factor kappaB and Fas/Fas ligand in induction of apoptosis and cell cycle arrest by saikosaponin d in human hepatoma cell lines. Cancer Lett. 213:213–221. 2004. View Article : Google Scholar : PubMed/NCBI
9	Wang Q, Zheng XL, Yang L, Shi F, Gao LB, Zhong YJ, Sun H, He F, Lin Y and Wang X: Reactive oxygen species-mediated apoptosis contributes to chemosensitization effect of saikosaponins on cisplatin-induced cytotoxicity in cancer cells. J Exp Clin Cancer Res. 29:1592010. View Article : Google Scholar
10	Hsu YL, Kuo PL and Lin CC: The proliferative inhibition and apoptotic mechanism of Saikosaponin D in human non-small cell lung cancer A549 cells. Life Sci. 75:1231–1242. 2004. View Article : Google Scholar : PubMed/NCBI
11	Kim BM and Hong SH: Sequential caspase-2 and caspase-8 activation is essential for saikosaponin a-induced apoptosis of human colon carcinoma cell lines. Apoptosis. 16:184–197. 2011. View Article : Google Scholar : PubMed/NCBI
12	Chen JC, Chang NW, Chung JG and Chen KC: Saikosaponin-A induces apoptotic mechanism in human breast MDA-MB-231 and MCF-7 cancer cells. Am J Chin Med. 31:363–377. 2003. View Article : Google Scholar : PubMed/NCBI
13	Zong Z, Fujikawa-Yamamoto K, Tanino M, Teraoka K, Yamagishi H and Odashima S: Saikosaponin b2-induced apoptosis of cultured B16 melanoma cell line through down-regulation of PKC activity. Biochem Biophys Res Commun. 219:480–485. 1996. View Article : Google Scholar : PubMed/NCBI
14	American Cancer Society. [http://www.cancer.org/cancer/prostatecancer/overviewguide/prostate-cancer-overview-key-statistics].
15	Marta GN, Hanna SA, Fernandes da Silva JL and de Carvalho HA: Screening for prostate cancer: an updated review. Expert Rev Anticancer Ther. 13:101–108. 2013. View Article : Google Scholar : PubMed/NCBI
16	Kollmeier MA and Zelefsky MJ: How to select the optimal therapy for early-stage prostate cancer. Crit Rev Oncol Hematol. 84(Suppl 1): e6–e15. 2012. View Article : Google Scholar : PubMed/NCBI
17	Drudge-Coates L and Turner B: Prostate cancer overview. Part 1: non-metastatic disease. Br J Nurs. 21:S23–S28. 2012. View Article : Google Scholar : PubMed/NCBI
18	Drudge-Coates L and Turner B: Prostate cancer overview. Part 2: metastatic prostate cancer. Br J Nurs. 21:S23–S24. S26–S28. 2012. View Article : Google Scholar : PubMed/NCBI
19	Twentyman PR and Luscombe M: A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer. 56:279–285. 1987. View Article : Google Scholar : PubMed/NCBI
20	Fuchs Y and Steller H: Programmed cell death in animal development and disease. Cell. 147:742–758. 2011. View Article : Google Scholar : PubMed/NCBI
21	Rhind N and Russell P: Signaling pathways that regulate cell division. Cold Spring Harb Perspect Biol. 4:a0059422012. View Article : Google Scholar
22	Dash BC and El-Deiry WS: Cell cycle checkpoint control mechanisms that can be disrupted in cancer. Methods Mol Biol. 280:99–161. 2004.PubMed/NCBI
23	Kitazumi I and Tsukahara M: Regulation of DNA fragmentation: the role of caspases and phosphorylation. FEBS J. 278:427–441. 2011. View Article : Google Scholar : PubMed/NCBI
24	Zimmermann KC, Bonzon C and Green DR: The machinery of programmed cell death. Pharmacol Ther. 92:57–70. 2001. View Article : Google Scholar : PubMed/NCBI
25	Mignotte B and Vayssiere JL: Mitochondria and apoptosis. Eur J Biochem. 252:1–15. 1998. View Article : Google Scholar
26	Armstrong JS: Mitochondria: a target for cancer therapy. Br J Pharmacol. 147:239–248. 2006. View Article : Google Scholar : PubMed/NCBI
27	Bras M, Queenan B and Susin SA: Programmed cell death via mitochondria: different modes of dying. Biochemistry (Mosc). 70:231–239. 2005. View Article : Google Scholar : PubMed/NCBI
28	Brenner D and Mak TW: Mitochondrial cell death effectors. Curr Opin Cell Biol. 21:871–877. 2009. View Article : Google Scholar
29	Chalah A and Khosravi-Far R: The mitochondrial death pathway. Adv Exp Med Biol. 615:25–45. 2008. View Article : Google Scholar
30	Pradelli LA, Bénéteau M and Ricci JE: Mitochondrial control of caspase-dependent and -independent cell death. Cell Mol Life Sci. 67:1589–1597. 2010. View Article : Google Scholar : PubMed/NCBI
31	Ola MS, Nawaz M and Ahsan H: Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem. 351:41–58. 2011. View Article : Google Scholar : PubMed/NCBI
32	García-Sáez AJ: The secrets of the Bcl-2 family. Cell Death Differ. 19:1733–1740. 2012.
33	Estaquier J, Vallette F, Vayssiere JL and Mignotte B: The mitochondrial pathways of apoptosis. Adv Exp Med Biol. 942:157–183. 2012. View Article : Google Scholar
34	Robertson JD, Orrenius S and Zhivotovsky B: Review: nuclear events in apoptosis. J Struct Biol. 129:346–358. 2000. View Article : Google Scholar : PubMed/NCBI
35	Wlodkowic D, Skommer J and Darzynkiewicz Z: Cytometry of apoptosis. Historical perspective and new advances. Exp Oncol. 34:255–262. 2012.PubMed/NCBI
36	Zinkel S, Gross A and Yang E: BCL2 family in DNA damage and cell cycle control. Cell Death Differ. 13:1351–1359. 2006. View Article : Google Scholar : PubMed/NCBI
37	Burlacu A: Regulation of apoptosis by Bcl-2 family proteins. J Cell Mol Med. 7:249–257. 2003. View Article : Google Scholar : PubMed/NCBI
38	Schultz DR and Harrington WJ Jr: Apoptosis: programmed cell death at a molecular level. Semin Arthritis Rheum. 32:345–369. 2003. View Article : Google Scholar : PubMed/NCBI
39	Gottlieb RA: Mitochondria and apoptosis. Biol Signals Recept. 10:147–161. 2001. View Article : Google Scholar : PubMed/NCBI
40	Fan J, Li X, Li P, Li N, Wang T, Shen H, Siow Y, Choy P and Gong Y: Saikosaponin-d attenuates the development of liver fibrosis by preventing hepatocyte injury. Biochem Cell Biol. 85:189–195. 2007.PubMed/NCBI
41	Besson A, Dowdy SF and Roberts JM: CDK inhibitors: cell cycle regulators and beyond. Dev Cell. 14:159–169. 2008. View Article : Google Scholar : PubMed/NCBI
42	Junttila MR and Evan GI: p53 - a Jack of all trades but master of none. Nat Rev Cancer. 9:821–829. 2009. View Article : Google Scholar : PubMed/NCBI
43	Abbas T and Dutta A: p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI